Sector
PharmaceuticalsOpen
₹696Prev. Close
₹694.5Turnover(Lac.)
₹18.08Day's High
₹696Day's Low
₹685.452 Week's High
₹937.9552 Week's Low
₹490Book Value
₹341.79Face Value
₹2Mkt Cap (₹ Cr.)
4,844.27P/E
40.19EPS
17.38Divi. Yield
0Revenue increased by 14.5% to ₹533 crore from ₹466 crore the previous year.
Bayshore Pharmaceuticals is a 100% subsidiary of Unichem Laboratories' parent firm, Ipca Laboratories Ltd.
According to the corporation, the observations have no influence on business continuity or supplies to the US market.
Here are some of the stocks that may see significant price movement today: Hindustan Unilever, Birla Estates, Lupin, etc.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 14.08 | 14.08 | 14.08 | 14.08 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 2,280.54 | 2,370.19 | 2,657.96 | 2,683.25 |
Net Worth | 2,294.62 | 2,384.27 | 2,672.04 | 2,697.33 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 942.92 | 1,123.97 | 904.88 | 669.33 |
yoy growth (%) | -16.1 | 24.21 | 35.19 | 16.19 |
Raw materials | -383.47 | -432.94 | -382.75 | -350.68 |
As % of sales | 40.66 | 38.51 | 42.29 | 52.39 |
Employee costs | -250.79 | -234.03 | -205.15 | -146.53 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | -86.74 | 65.64 | -63.81 | -121.55 |
Depreciation | -83.18 | -75.89 | -71.08 | -45.04 |
Tax paid | 31.31 | -11.56 | 7.49 | 0.14 |
Working capital | 139.57 | -55.07 | -268.15 | 642.72 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -16.1 | 24.21 | 35.19 | 16.19 |
Op profit growth | -145.62 | -205.35 | -33.48 | 134.8 |
EBIT growth | -226.48 | -207.06 | -47.18 | 31.19 |
Net profit growth | -202.49 | -196.03 | -102.2 | 2,361.41 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 1,785.11 | 1,343.02 | 1,269.83 | 1,235.14 | 1,103.71 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,785.11 | 1,343.02 | 1,269.83 | 1,235.14 | 1,103.71 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 31.59 | 38.52 | 47.51 | 50.19 | 92.13 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,698.35 | 129.24 | 4,07,155.15 | 1,181.05 | 0.8 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,549.7 | 71.05 | 1,47,295.24 | 594 | 0.54 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,444.25 | 25.07 | 1,16,664.33 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183.9 | 59.03 | 1,07,673.27 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,458.1 | 52.42 | 1,01,358.17 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Independent Non Exe. Director
Priti Puri
Non-Exec & Non-Independent Dir
Pranay Godha
Managing Director
Pabitra Bhattacharya
Company Sec. & Compli. Officer
Pradeep Bhandari
Chairman (Non-Executive)
Prakash A Mody
Independent Director
Anand T Kusre
Independent Director
Arun Todarwal
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Unichem Laboratories Ltd
Summary
Unichem Laboratories Limited is an India-based pharmaceutical company, which manufactures active pharmaceutical ingredients. The company operates through four divisions, namely Unichem Pharma Division, Unichem Specialities Division, Unisearch Division and Neu-Foreva Division. The company is headquartered in Mumbai with five manufacturing facilities located at Roha in Maharashtra, Goa, Ghaziabad in Uttar Pradesh, Pithampur in Madhya Pradesh and Baddi in Himachal Pradesh.The companys facilities enjoy credible certifications, the Goa plant was approved by UK MHRA, MCC (South Africa), WHO (Geneva) and TGA (Australia). The Baddi plant was approved by UK MHRA and MCC (South Africa). The company received ISO 9001:2000 for all their plants and corporate office. Also, they received ISO 14001:2004 certificates for their formulation plants located at Goa, Ghaziabad and Baddi and the corporate office at Mumbai.Unichem Laboratories Limited was incorporated in 1962. The company was formed by Dr. Prakash Amrut Mody to take over a proprietary business set up in 1944 in Mumbai. They made a foreign collaboration with UCB for bulk drugs and set up first formulation plant at Jogeshwari. In the year 1963, they made a tie up with Uni Sankyo Co-Marketing formulations.In the year 1968, the company set up formulations plant Ghaziabad and in the year 1976, they set up a fine chemicals unit at Roha. In the year 1984, the company entered an agreement with Upjohn and set up Unisearch Ltd. Also, they ente
Read More
The Unichem Laboratories Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹688.05 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Unichem Laboratories Ltd is ₹4844.27 Cr. as of 02 Apr ‘25
The PE and PB ratios of Unichem Laboratories Ltd is 40.19 and 2.08 as of 02 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Unichem Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Unichem Laboratories Ltd is ₹490 and ₹937.95 as of 02 Apr ‘25
Unichem Laboratories Ltd's CAGR for 5 Years at 37.08%, 3 Years at 37.05%, 1 Year at 40.96%, 6 Month at 2.38%, 3 Month at -5.56% and 1 Month at 7.15%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.